how long have glp 1 medications been around Market Overview: GLP-1 Agonists and the Obesity Market | Blog Glucagon-like peptide-1 receptor: mechanisms and

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have been pivotal for obesity treatment, achieving 1525 % weight loss over 1224 months, but questions remain about the potential influence of concomitant losses in muscle mass

No injections

glucagon-like peptide-1 agonist, -1)...

This narrative reviewaims to analyzecurrent findings on the beneficial and adverse ocular effects of GLP-1RAsuse, highlighting studies that elucidate the harmful causes, such as retinal microvascular dysregulation, inflammatory modulation, oxidative stress,osmotic dysregulation from sorbitol accumulation,and metabolic shifts

Glucagon-like peptide-1 (GLP-1) is an incretin hormone released from gut enteroendocrine cells that modulates glucose metabolism by controlling insulin excretion and glucagon secretion and inhibits gastric emptying leading to decreased food intake, thus limiting weight gain

These hormones then communicate with the appetite-suppression pathway in the brain, reducing feelings of appetite, cravings, and caloric intake